E. de Pablo

Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting.

D. Serrano, R. Fernández-García, M. P. Ballesteros, 2017, International journal of pharmaceutics.

Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?

D. Serrano, J. Torrado, R. Fernández-García, 2017, Annals of translational medicine.

Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections.

A. Healy, M. Dea-Ayuela, F. Bolás-Fernández, 2017, Molecular pharmaceutics.

Analgesic and anti‐inflammatory controlled‐released injectable microemulsion: Pseudo‐ternary phase diagrams, in vitro, ex vivo and in vivo evaluation

D. Serrano, K. Slowing, M. P. Ballesteros, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers.

A. Healy, M. Dea-Ayuela, D. Serrano, 2023, International journal of pharmaceutics.